# Lysosomal payload transport

Source: https://onco.cc/terms/lysosomal-payload-egress/  
OnCo record `lysosomal-payload-egress` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Releasing a drug inside a cell's recycling compartment is one step in delivery. Some released drug forms also need transport into the rest of the cell before they can act.

## Summary

Primary experiments identified SLC46A3 as a transporter involved in movement of noncleavable maytansine-conjugate catabolites from lysosomes to the cytoplasm. Reducing SLC46A3 affected the studied maytansine conjugates, while the tested MMAF conjugates behaved differently. Transporter dependence is therefore specific to the released species and construct. It is a mechanistic research finding, not a validated clinical selection test for every antibody-drug conjugate.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: lysosomal payload egress; SLC46A3 payload transport; lysosomal payload trapping

## Sources

- SLC46A3 and maytansine-catabolite transport (2015): https://doi.org/10.1158/0008-5472.CAN-15-1610

## Connected records

- terms: [Antibody internalization and intracellular trafficking](https://onco.cc/terms/antibody-internalization-trafficking/), [DM1](https://onco.cc/terms/dm1/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [MMAF](https://onco.cc/terms/mmaf/)
- drugs: [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/lysosomal-payload-egress.json